Actinium Pharmaceuticals
ATNM
59 hedge funds and large institutions have $30.5M invested in Actinium Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1,361% more capital invested
Capital invested by funds: $2.09M → $30.5M (+$28.4M)
800% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 2
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
40% more funds holding
Funds holding: 42 → 59 (+17)
0.52% more ownership
Funds ownership: 0.22% → 0.73% (+0.52%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$9.34M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.59M |
| 3 |
SCM
Sio Capital Management
New York
|
+$2.06M |
| 4 |
BlackRock
New York
|
+$1.77M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$14.6K |
| 2 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$8K |
| 3 |
Jane Street
New York
|
-$3K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$3K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$1.24K |
ATNM Hedge Fund Activity: Q2 2020 in Review
59 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q2 2020, worth a combined $30.5M — up 1,361% from $2.09M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ATNM positions and 3 closed out — a net gain of 17 holders — while 18 added to existing stakes and 2 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.34M. The largest seller was UBS Group, cutting an estimated $14.6K.
- 59 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q2 2020, up from 42 in Q1 2020.
- Funds reported $30.5M of Actinium Pharmaceuticals stock for Q2 2020, up 1,361% quarter-over-quarter.
- 20 funds opened new Actinium Pharmaceuticals positions in Q2 2020 and 3 closed out, a net change of +17 holders.
- The largest Actinium Pharmaceuticals buyer in Q2 2020 was Consonance Capital Management, an estimated $9.34M added.
- The largest Actinium Pharmaceuticals seller in Q2 2020 was UBS Group, an estimated $14.6K sold.
Based on aggregated 13F filings for Q2 2020.